Vonoprazan/amoxicillin/clarithromycin

{{Short description|Medication}}

{{Use American English|date=May 2022}}

{{Use dmy dates|date=May 2022}}

{{Infobox drug

| drug_name =

| type = combo

| image = VONOSAP Pack 400.jpg

| component1 = Vonoprazan

| class1 = Potassium-competitive acid blocker

| component2 = Amoxicillin

| class2 = Beta-lactam antibiotic

| component3 = Clarithromycin

| class3 = Macrolide antibiotic

| pronounce =

| tradename = Vonosap, Voquezna Triple Pak

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID = Voquezna

| licence_US =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration =

| ATCvet =

| ATC_prefix = A02

| ATC_suffix = BD14

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit | work = DailyMed | publisher = U.S. National Library of Medicine | date=21 June 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86 | access-date=3 July 2022 | archive-date=3 July 2022 | archive-url=https://web.archive.org/web/20220703054730/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86 | url-status=live }}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status = Rx-only

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D10775

| ChEBI =

| ChEMBL =

| synonyms =

}}

Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.{{cite journal | vauthors = Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S | title = Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis | journal = Advances in Therapy | volume = 38 | issue = 7 | pages = 3937–3947 | date = July 2021 | pmid = 34091865 | pmc = 8280045 | doi = 10.1007/s12325-021-01784-w }} It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.

It was approved for medical use in Japan in 2016,{{cite web | title=Vonosap pack 400, Vonosap pack 800 and Vonopion pack (triple-drug blister packs containing Takecab tablet) Now Available for Helicobacter pylori[*] Eradication in Japan | website=Takeda | date=7 June 2016 | url=https://www.takeda.com/newsroom/newsreleases/2016/vonosap-pack-400-vonosap-pack-800-and-vonopion-pack-triple-drug-blister-packs-containing-takecab-tablet-now-available-for-helicobacter-pylori-eradication-in-japan/ | access-date=9 May 2022 | archive-date=10 May 2022 | archive-url=https://web.archive.org/web/20220510031615/https://www.takeda.com/newsroom/newsreleases/2016/vonosap-pack-400-vonosap-pack-800-and-vonopion-pack-triple-drug-blister-packs-containing-takecab-tablet-now-available-for-helicobacter-pylori-eradication-in-japan/ | url-status=live }} and in the United States in May 2022.{{cite press release | title=Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults | publisher=Phathom Pharmaceuticals | via=GlobeNewswire | date=3 May 2022 | url=https://www.globenewswire.com/en/news-release/2022/05/03/2435147/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-VOQUEZNA-TRIPLE-PAK-vonoprazan-amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amoxicillin-for-the-Treatment-of-H-pylo.html | access-date=9 May 2022 | archive-date=10 May 2022 | archive-url=https://web.archive.org/web/20220510034341/https://www.globenewswire.com/en/news-release/2022/05/03/2435147/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-VOQUEZNA-TRIPLE-PAK-vonoprazan-amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amoxicillin-for-the-Treatment-of-H-pylo.html | url-status=live }}{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000,%20215153Orig1s000ltr.pdf |title=FDA NDA approval |website=U.S. Food and Drug Administration (FDA) |access-date=12 May 2022 |archive-date=12 May 2022 |archive-url=https://web.archive.org/web/20220512000404/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000,%20215153Orig1s000ltr.pdf |url-status=dead }}{{Cite web|url=https://www.drugs.com/history/voquezna-triple-pak.html|title=Voquezna Triple Pak (amoxicillin, clarithromycin, and vonoprazan) FDA Approval History|website=Drugs.com}} The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.{{cite web | title=Advancing Health Through Innovation: New Drug Therapy Approvals 2022 | website=U.S. Food and Drug Administration (FDA) | date=10 January 2023 | url=https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022 | archive-url=https://web.archive.org/web/20230110192023/https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022 | url-status=dead | archive-date=10 January 2023 | access-date=22 January 2023}} {{PD-notice}}{{cite report | title=New Drug Therapy Approvals 2022 | website=U.S. Food and Drug Administration (FDA) | date=January 2024 | url=https://www.fda.gov/media/164429/download | format=PDF | access-date=14 January 2024 | archive-url=https://web.archive.org/web/20240114065648/https://www.fda.gov/media/164429/download | archive-date=14 January 2024 | url-status=dead }} {{PD-notice}}